Importantly, combinatorial targeting of BCL-2 and MCL-1 is tolerated in mice and is under investigation in clinical trials of hematological cancers (NCT03672695, NCT04702425) [111–114]. The gene discussed is MCL1; the disease is hematopoietic and lymphoid cell neoplasm.